Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at http://www.Nanoviricides.com . We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you should not consider it part of this Annual Report.
Partnerships TheraCour Pharma, Inc. (related party): platform IP licenses; 15% net-sales royalty; development activities performed by TheraCour; KMPL (India) sponsored the Phase Ia/Ib trial
Indications
COVID-19(Phase 1)
MPox(Phase 1)
Smallpox(Phase 1)
Measles(Phase 1)
RSV(Phase 1)
Status note Broad-spectrum antiviral nanoviricide. Phase Ia/Ib safety/tolerability trial of NV-CoV-2 oral formulations (API NV-387) in healthy subjects completed (KMPL-sponsored, India); final CSR pending. Phase II planned (MPox first); FDA Orphan Drug Designation granted for measles treatment Apr 27, 2026; pre-IND engagements planned for MPox, Smallpox, Measles and RSV.
Partnerships TheraCour Pharma, Inc. (related party): platform IP licenses; 15% net-sales royalty
Indications
Shingles (VZV)(Preclinical)
HSV-1 cold sores(Preclinical)
HSV-2 genital ulcers(Preclinical)
Status note Preclinical. IND-enabling safety-pharmacology studies completed for the Shingles skin-cream formulation toward a US IND filing; systemic formulation also in development.
NV-HIV-1
Preclinical · ActiveModality: nanoviricide
Target HIV
Partnerships TheraCour Pharma, Inc. (related party): platform IP licenses; 15% net-sales royalty
Indications
HIV(Preclinical)
Status note Preclinical; company states activity in an HIV mouse model warrants further regulatory development.
Partnerships KMPL (India): out-license for clinical development and commercialization in India
Indications
COVID-19(Preclinical)
Status note Second COVID-19 clinical-test candidate out-licensed to KMPL; no clinical trial disclosed.
Per-asset detail extracted from the 10-Q filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.